

CBSA NEWS IN REVIEW



A BRIEF OVERVIEW OF COLORADO'S MEDICAL DEVICE AND BIOPHARMA INDUSTRIES

4 April – 10 April

COMPANY SPOTLIGHT

- **Array BioPharma Inc.** (Boulder) announced that the first patient has been dosed in its Phase 1 clinical trial of ARRY-403 in Type 2 diabetes patients. The Phase 1 study will test ARRY-403 in single- and multiple-dose escalation studies to evaluate safety, tolerability, exposure, and blood glucose control in Type 2 diabetics.
- **OPX Biotechnologies** (Boulder) announced it has raised an additional \$5.4M bringing its Series B Round total to \$17.5M. OPX is working to cost-effectively synthesize fuels and green chemistry products from renewable biomass feed stocks using its proprietary OPX EDGE™ (Efficiency Directed Genome Engineering) technology platform.
- **Baxa Corporation** (Englewood) a leading developer of technology for the safe handling, packaging and administration of fluid medications, has joined the social media dance by hosting both a corporate Facebook page and a LinkedIn Business Group.
- Five Colorado companies were among the 15 companies that presented at the Company Showcase held during BIOZONA, Arizona's Annual Bioscience Industry Conference, held on April 7 in Phoenix.
 - **KromaTiD, Inc.** (Fort Collins): Category, Diagnostics, Assays & Services
 - **Pharmatech Oncology** (Denver): Diagnostics, Assays & Services
 - **ApopLogic Pharmaceuticals** (Aurora): Therapeutics and Vaccines
 - **NeuroQuest Therapeutics** (Grand Junction): Devices & Drug Delivery Systems
- **Quest Product Development Corp.** (Wheat Ridge): Devices & Drug Delivery Systems

PEOPLE

- **N30 Pharma** (Boulder) has named several new members to its scientific advisory board which will be chaired by Dr. Joseph Loscalzo. The new members of the board are Dr. Augustine Choi, Dr. Michael Marletta, Dr. William Sessa, and Dr. Joseph Vita.

SQUARE PEGS

- Scientists have developed a new label-free approach to evaluate the phosphorylation state of proteins. This method was used to identify a new protein involved in the regulation on melanoma invasion. The study was authored by Dr. Natalie G. Ahn from the Department of Chemistry and Biochemistry at the University of Colorado and the Howard Hughes Medical Institute.

UPCOMING EVENTS

- **CBSA's annual all member meeting** will take place from 4:00-6:00 pm on Tuesday, April 21 at the Colorado National Golf Club (formerly Vista Ridge) in Erie. The meeting will offer members a chance to learn more about association business including committee activities and to vote on the new officers and directors of the association. More information is available [here](#).
- Colorado State University will host the 4th annual BioTech Connect on April 21 beginning at 8 am. The event seeks to bring the BioTech community of Northern

Colorado together with students and faculty at Colorado State University. More information and registration details are available [here](#).

- The next BioBreakfast will occur on April 29 at 7:30 at the Anschutz Medical Campus and feature “Two Colorado Companies Making a Splash.” More details and registration information are available [here](#).

LEGISLATIVE UPDATE

- CBSA’s lobbying team, have provided this week's legislative report.

**Advance Colorado Center • 1625 Broadway Suite 950 • Denver Colorado 80202
Phone: 303-592-4073 • Fax: 303-592-4081 • www.CoBioScience.com**